Given the critical role of HOXA5 in promoting the M2 macrophage switch in chronic inflammation, targeting its immunomodulatory action may provide therapeutic benefits and alleviate obesity-related inflammation and metabolic abnormalities. This evidence concerns the gene HOXA5 and obesity due to melanocortin 4 receptor deficiency.